Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Anpac Bio Medical Science Co Ltd is a biotechnology business based in the US. Anpac Bio Medical Science Co shares (ANPC) are listed on the NASDAQ and all prices are listed in US Dollars. Anpac Bio Medical Science Co employs 89 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.29 |
|---|---|
| 52-week range | $0.20 - $4.52 |
| 50-day moving average | $0.32 |
| 200-day moving average | $1.28 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.04 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.29 from 2022-06-28
| 1 week (2022-06-22) | 0.35% |
|---|---|
| 1 month (2022-05-27) | -0.34% |
| 3 months (2022-03-29) | -34.09% |
| 6 months (2021-12-29) | -72.38% |
| 1 year (2021-06-29) | -92.91% |
|---|---|
| 2 years (2020-06-29) | -94.30% |
| 3 years (2019-06-25) | N/A |
| 5 years (2017-06-25) | N/A |
| Revenue TTM | $17.8 million |
|---|---|
| Gross profit TTM | $12.3 million |
| Return on assets TTM | -92.03% |
| Return on equity TTM | -936.34% |
| Profit margin | 0% |
| Book value | $0.42 |
| Market capitalisation | $7.4 million |
TTM: trailing 12 months
We're not expecting Anpac Bio Medical Science Co to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Anpac Bio Medical Science Co's shares have ranged in value from as little as $0.203 up to $4.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anpac Bio Medical Science Co's is 1.5679. This would suggest that Anpac Bio Medical Science Co's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Anpac Bio Medical Science Co's beta into context you can compare it against those of similar companies.
AnPac Bio-Medical Science Co. , Ltd. , a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
